RxDoctor Payments Data

Stephen Mooney, MD

Internal Medicine · Lexington, KYNPI 1003815622

Payments from drug & device makers

$7,086in general payments, 2019–2025

Across 387 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$878
  • AstraZeneca$708
  • Boehringer Ingelheim$605
  • AbbVie$525
  • Novo Nordisk$491
  • Johnson & Johnson$383
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,086100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,086 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$138,133
Medicare patients
289
Services billed
1,579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin149$158,356
EliquisApixaban102$91,464
OzempicSemaglutide68$81,590
MounjaroTirzepatide45$57,572
XareltoRivaroxaban25$32,180
FarxigaDapagliflozin Propanediol28$25,645
MyrbetriqMirabegron26$21,086
LinzessLinaclotide16$16,837
JanuviaSitagliptin Phosphate12$13,253
Icosapent Ethyl18$6,488
Spiriva HandihalerTiotropium Bromide11$5,534
GemtesaVibegron19$5,499
Potassium Chloride164$4,848
Atorvastatin Calcium452$4,323
Rosuvastatin Calcium444$3,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$605$158,356149 claims
PfizerEliquis$335$91,464102 claims
Novo NordiskOzempic$491$81,59068 claims
Lilly USA, LLCMounjaro$878$57,57245 claims
Johnson & JohnsonXarelto$383$32,18025 claims
AstraZenecaFarxiga$708$25,64528 claims
Astellas Pharma US IncMyrbetriq$311$21,08626 claims
AbbVieLinzess, Synthroid$525$18,94991 claims
MerckJanuvia$58$13,25312 claims
Sumitomo Pharma America, Inc.Gemtesa$81$5,49919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →